Neurocrine Biosciences (NBIX) has an average rating of Outperform and price targets ranging from $76 to $154, according to analysts polled by Capital IQ....
Neurocrine Biosciences (NBIX) shares were down 4% in Tuesday afternoon trading after RBC downgraded the biopharmaceutical company's stock to sector perform...
Neurocrine Biosciences (NBIX) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $76 to...
Xenon Pharmaceuticals (XENE) said Wednesday said it was set to receive a payment of $15 million from its epilepsy joint venture partner Neurocrine...
Neurocrine Biosciences (NBIX) has an average rating of outperform and price targets ranging from $76 to $154, according to analysts polled by Capital IQ....
Neurocrine Biosciences (NBIX) on Thursday reported preliminary Ingrezza drug sales of about $301 million for Q4 and about $1.1 billion for the full year...
Neurocrine Biosciences (NBIX) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $76 to...
Neurocrine Biosciences (NBIX) has an average rating of Outperform and price targets ranging from $76 to $154, according to analysts polled by Capital IQ....
Neurocrine Biosciences' (NBIX) positive results from a late-stage study of its experimental Ingrezza valbenazine drug in adults with chorea tied to...
Neurocrine Biosciences (NBIX) has an average outperform rating and a price target range of $76 to $154, according to analysts polled by Capital IQ. (MT...